Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: " Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas | Journal of Experimental Clinical Cancer Research Liu et al. Journal of Experimental Clinical Cancer Research 2011 30 76 http www.jeccr.eom content 30 1 76 RESEARCH Open Access Downregulation of CDKN2A and suppression of cyclin D1 gene expressions in malignant gliomas Weidong Liu Guohua Lv Yawei Li Lei li and Bing Wang Abstract Background Malignant gliomas are the most common in central nervous system cancer. Genome-wide association study identifies that CDKN2A was a susceptibility loci for glioma. The CDKN2A cyclin-dependent kinase 4 6 Retinoblastoma protein Rb pathway is thought to play a crucial role in malignant gliomas pathogenesis. We have investigated the expression of CDKN2A for potential correlations with malignant gliomas grade and potential role of CDKN2A on malignant gliomas pathogenesis. Methods Tumour tissue samples from 61 patients suffering from malignant gliomas were investigated. The expression levels of CDKN2A were detected using immunohistochemical staining and western blot. Overexpression and knockdown of CDKN2A were performed in human glioma cell lines. Subsequently colony formation growth curves and CDKN2A-Cyclin-Rb pathway were analyzed. Results Here we show that a lower expression of CDKN2A and a higher expression of cyclin D1 in the patients with high-grade malignant gliomas than low-grade gliomas respectively. Moreover overexpression of CDKN2A inhibits growth of glioma cell lines by suppression of cyclin D1 gene expression. Conclusions Our study suggests that CDKN2A as a malignant gliomas suppressor gene appears to be useful for predicting behaviour of high-grade malignant gliomas. CDKN2A-Cyclin-Rb pathway plays a key role on malignant gliomas formation and that therapeutic targeting of this pathway may be useful in malignant gliomas treatment. Background Glioma is the most frequent primary intracranial tumour in both adults and children. Their incidence rate is about 6.42 cases 100 000 1 . The molecular genetic alterations with the .